Tempest Therapeutics Stock Today
TPST Stock | USD 6.30 0.36 5.41% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Tempest Therapeutics is selling for under 6.30 as of the 19th of July 2025; that is 5.41 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 6.25. Tempest Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of April 2025 and ending today, the 19th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of November 2012 | Category Healthcare | Classification Health Care |
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc. Tempest Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 3.68 M outstanding shares of which 365.69 K shares are at this time shorted by private and institutional investors with about 2.24 trading days to cover. More on Tempest Therapeutics
Moving against Tempest Stock
Tempest Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
President CEO | LLM JD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTempest Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tempest Therapeutics' financial leverage. It provides some insight into what part of Tempest Therapeutics' total assets is financed by creditors.
|
Tempest Therapeutics (TPST) is traded on NASDAQ Exchange in USA. It is located in 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005 and employs 24 people. Tempest Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.52 M. Tempest Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.68 M outstanding shares of which 365.69 K shares are at this time shorted by private and institutional investors with about 2.24 trading days to cover.
Tempest Therapeutics currently holds about 51.62 M in cash with (33.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95.
Check Tempest Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Tempest Therapeutics is $24.52 Million. About 88.15 % of Tempest Therapeutics outstanding shares are held by general public with 0.12 (%) owned by insiders and only 11.73 % by institutional holders. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Tempest Ownership Details
Tempest Stock Institutional Holders
Instituion | Recorded On | Shares | |
Advisor Group Holdings, Inc. | 2024-12-31 | 25.4 K | |
Simplex Trading, Llc | 2024-12-31 | 18.9 K | |
Maytech Global Investments, Llc | 2024-12-31 | 10 K | |
Federation Des Caisses Desjardins Du Quebec | 2024-12-31 | 3.8 K | |
Millstone Evans Group, Llc | 2024-12-31 | 800 | |
Sbi Securities Co Ltd | 2025-03-31 | 767 | |
Bank Of America Corp | 2024-12-31 | 331 | |
Parallel Advisors, Llc | 2025-03-31 | 236 | |
Atlantic Trust Group, Llc | 2024-12-31 | 133 | |
Versant Venture Management Llc | 2025-03-31 | 3.5 M | |
Blackrock Inc | 2024-12-31 | 551.9 K |
Tempest Therapeutics Historical Income Statement
Tempest Stock Against Markets
Tempest Therapeutics Corporate Management
Nicholas Maestas | VP Secretary | Profile | |
Justin CPA | Treasurer Controller | Profile | |
Dr Dubensky | Pres Director | Profile | |
Justin Trojanowski | Treasurer Controller | Profile | |
RAC Sakai | Head Quality | Profile | |
Samuel MD | Executive Officer | Profile | |
Petpiboon Prasit | Acting Director | Profile |
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.